Diagonal Therapeutics

We’re excited to share that Diagonal Therapeutics has been nominated for the Emerging Life Science Company of the Year award at the 12th Annual #NEVYs24! Thank you to the New England Venture Capital Association (NEVCA) for recognizing us! We can’t wait to join our fellow innovators and celebrate at the #NEVYsSurvivor themed event on December 5th! Check out the full list of nominees here: bit.ly/48yZ7pV

We were delighted to spend last week at the 15th International HHT Scientific Conference. Cure HHT has done a tremendous job elevating the medical understanding and awareness of this rare disease, and we were honored to participate. We, along with our scientific and clinical collaborators, Philippe Marambaud, Ph.D. (Feinstein Institutes for Medical Research) and Hanny Al-Samkari, M.D. (MGH), gave three presentations. We reviewed our scientific approach, highlighted the need for better treatment options, and presented emerging research on the overall healthcare costs associated with HHT. Thanks to the organizing committee from France and all our colleagues who were there to support and share new ideas.

We are excited to participate with multiple presentations at the upcoming 15th HHT International Scientific Conference, hosted by Cure HHT. We will showcase the potential of our ALK1 agonist antibody for people suffering from HHT. Our President and CEO, Alexey "Alex" Lugovskoy, comments. https://bit.ly/3Y04IB3 #antibody #agonistantibodies #innovation

Today we announced our participation with multiple presentations at Cure HHT’s 15th HHT International Scientific Conference. Throughout the conference, we will present an overview of our ALK1 agonist antibody designed to target the root cause of HHT. Our scientific collaborator, Philippe Marambaud of the Feinstein Institutes for Medical Research, will also present a detailed characterization of our approach in multiple HHT-relevant in vitro and in vivo models. We look forward to the meeting and special thanks to Cure HHT for inviting us to speak.?https://bit.ly/3Y04IB3

Recently, our CEO, Alexey "Alex" Lugovskoy gave a talk at the #Antibody Series 2024 on how we use artificial intelligence and computational methods to facilitate the discovery of agonist antibodies against challenging-?to-drug multimeric receptor complexes, including our lead agonist molecules designed to correct signaling in the people with #HHT. Please watch the full presentation here:?https://lnkd.in/e4288Fut

Next week, our own Andy Sullivan and JC Hus will present at the 22nd Annual Discovery on Target meeting in Boston. Andy will review the potential of bivalent agonist antibodies as next-generation immunological therapies, and JC will present on how we combine #machinelearning and physics-based methods to design and optimize our therapies. We hope to see you there!?? https://lnkd.in/ene8XC8F

We are fundamentally changing the way agonist antibody therapies are developed. The biopharmaceutical industry has a robust, growing toolkit of methods to inhibit disease-associated pathways. However, there lacks a systematic and pharmacologic approach to activating biological pathways which could hold the answer to treating diseases caused by deficient signaling. Our platform addresses this unmet need by rapidly identifying antibodies that activate key pathways. To learn more, visit: https://lnkd.in/eqk49hrX #agonistantibodies ?#drugdevelopment #biotechnology #drugdiscovery

It's been a busy and exciting summer for Diagonal! We recently moved out of an incubator space and into our very own office in Arsenal Yards, Watertown. The team has been hard at work setting up our new lab. What better way to celebrate and wrap up the summer than with a trip on the famous Boston Duck Tour!?

Thanks to BioCentury Inc.’s Danielle Golovin, Ph.D. for featuring us in this emerging company profile. Danielle and our CEO Alexey "Alex" Lugovskoy had a great discussion about how Diagonal Therapeutics?is solving the historical challenge that has limited agonist antibody drug discovery. Our approach skillfully blends computational and experimental techniques to reproducibly find molecules that trigger the signaling of any receptor complex, thus creating new medicines for disorders where patients have limited or no treatment options. https://lnkd.in/enikPXYM

Dr. Philippe Marambaud’s work developing new preclinical models helps?improve our understanding of HHT and test novel therapies.?Congrats for being recognized as a Changemaker by Cure HHT!